Animal studies demonstrate that mTOR inhibition improves cystic disease and kidney function (Pema et al., 2016; Su et al., 2022), however, metanalysis of cIinical data with ADPKD patients receiving rapamycin, sirolimus, or everolimus did not support a significant influence on renal progression (Lin et al., 2019). This evidence concerns the gene MTOR and autosomal dominant polycystic kidney disease.